IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re *Inter Partes* Review of:	)
U.S. Patent No. 9,138,432 B2	)
Issued: Sept. 22, 2015	)
Application No.: 14/150,575	)
Filing Date: Jan. 8, 2014	)

For: **Methods for the Administration of Iloperidone**

FILED VIA PRPS

PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 9,138,432

TABLE OF CONTENTS

Page

Exhibit List

1001 U.S. Patent No. 9,138,432 (the "'432 Patent")

1002 File History for the '432 Patent (from the USPTO public Patent Application Information Retrieval (PAIR) database, www.uspto.gov, excluding foreign references)

1003 Declaration of David Fogelson, M.D. in Support of Petition for *Inter Partes* Review of U.S. Patent No. 9,138,432

1004 Curriculum Vitae of David Fogelson, M.D.

1005 U.S. Department of Health and Human Services, Food and Drug Administration ("FDA"), *Guidance for Industry, In Vivo Drug Metabolism/Drug Interaction Studies – Study Design, Data Analysis, and Recommendations for Dosing and Labeling* (November 1999) (*available at* http://www.fda.gov/OHRMS/DOCKETS/98fr/994718gd.pdf) (accessed February 22, 2016) ("FDA Guidance 1999")

1006 A.E. Mutlib *et al.*, *Application of Liquid Chromatography/Mass Spectrometry in Accelerating the Identification of Human Liver Cytochrome P450 Isoforms Involved in the Metabolism of Iloperidone*, 286 J. PHARM. & EXPERIMENTAL THERAPEUTICS 1285-93 (September 1998) ("Mutlib")

1007 K. Brøsen, *Differences in Interactions of SSRIs*, 13 INT'L CLINICAL PSYCHOPHARM. S45-47 (September 1998) ("Brøsen")

1008 *Physicians' Desk Reference* (58th ed. 2004) (Montvale, NJ; Thompson PDR, November 2003) ("PDR 2004"), comprising: Abilify Official Labeling, Bristol-Myers Squibb Company (revised May 2003) at 1034-38, and Otsuka America Pharmaceutical, Inc. (revised May 2003) at 2496-500 (the "PDR Abilify Label"); and Strattera Official Labeling, Eli Lilly and Company (revised March 5, 2003) at 1850-54 (the "Strattera Label")

1009 FDA Official Website, Drug Approval Package: Abilify (Aripiprazole) NDA #21-436, November 15, 2002 (the "Abilify Approval Package") (*available at* http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-436_Abilify.cfm) (webpage created March 7, 2003), linking to: "Approval Letter(s)," November 15, 2002 Letter from FDA to Otsuka

Pharmaceutical Co., Ltd. (the "Abilify Approval Letter") (*available at* http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-436_Abilify_Approv.pdf); and "Printed Labeling," Final Printed Labeling (the "FPL Abilify Label") (*available at* http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21436_Abilify_prntlbl.pdf) (accessed February 23, 2016)

1010 N.E. Mealy *et al.*, *Annual Review 2002: Psychopharmacologic Drugs*, 27 DRUGS OF THE FUTURE 995-1027 (October 2002) ("Mealy")

1011 K.K. Jain, *An Assessment of Iloperidone for the Treatment of Schizophrenia*, 9 EXPERT OPINION ON INVESTIGATIONAL DRUGS 2935-43 (December 2000) ("Jain")

1012 U.S. Patent Publication No. 2003/0144220, "Use of CYP2D6 Inhibitors in Combination Therapies," filed March 21, 2000, published July 31, 2003 ("Obach")

1013 S.M. Cheer *et al.*, *Fluoxetine, A Review of its Therapeutic Potential in the Treatment of Depression Associated with Physical Illness*, 61 DRUGS 81-110 (January 2001) ("Cheer")

1014 International Publication No. WO 01/79554, "Genetic Diagnosis for QT Prolongation Related Adverse Drug Reactions," filed April 13, 2001, published October 25, 2001 ("Woosley")

1015 U.S. Department of Health and Human Services, Food and Drug Administration ("FDA"), *Guidance for Industry, Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro* (April 1997) (*available at* http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM142439.pdf) (accessed February 22, 2016) ("FDA Guidance 1997")

1016 R.R. Shah, *Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes: Potential Tool for Improving Clinical Drug Development and Prescribing*, 27 DRUG SAFETY 145-72 (March 2004) ("Shah")

1017 *Physicians' Desk Reference* (56th ed. 2002), Prozac Official Labeling, Dista Products Company (revised February 28, 2001, product information prepared June 2001) at 1238-43 (the "Prozac Label")

1018 FDA Official Website, Drugs@FDA: FDA Approved Drug Products,

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.